MTOR and Hyperglycemia: Although there might be a possibility of mTOR inhibitors as candidates of host-directed therapy against multi-drug-resistance (MDR)- or extensively drug-resistance (XDR)-TB, the impact for mTOR inhibitor-based adjunctive therapy in the context of TB remains to be determined, because of serious side effects such as hyperglycemia and immunosuppression (Singh and Subbian, 2018).